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Ten Novel Mutations in the NR5A1 Gene Cause
Disordered Sex Development in 46,XY and Ovarian
Insufficiency in 46,XX Individuals
N. Camats, A. V. Pandey, M. Ferna´ndez-Cancio, P. Andaluz, M. Janner,
N. Tora´n, F. Moreno, A. Bereket, T. Akcay, E. García-García, M. T. Mun˜oz,
R. Gracia, M. Nistal, L. Castan˜o, P. E. Mullis, A. Carrascosa, L. Audí,*
and C. E. Flu¨ck*†
Context: Steroidogenic factor-1 (SF-1/NR5A1) is a nuclear receptor that regulates adrenal and
reproductive development and function. NR5A1mutations have been detected in 46,XY individ-
uals with disorders of sexual development (DSD) but apparently normal adrenal function and in
46,XX women with normal sexual development yet primary ovarian insufficiency (POI).
Objective: A group of 100 46,XY DSD and two POI was studied for NR5A1 mutations and their
impact.
Design: Clinical, biochemical, histological, genetic, and functional characteristics of the patients
with NR5A1 mutations are reported.
Setting: Patients were referred from different centers in Spain, Switzerland, and Turkey. Histo-
logical and genetic studies were performed in Barcelona, Spain. In vitro studies were performed
in Bern, Switzerland.
Patients:Atotal of 65 Spanishand35Turkishpatientswith46,XYDSDand twoSwiss 46,XXpatients
with POI were investigated.
Main Outcome: Ten novel heterozygote NR5A1mutations were detected and characterized (five
missense, one nonsense, three frameshift mutations, and one duplication).
Results: The novelNR5A1mutationswere tested in vitro by promoter transactivation assays show-
inggrossly reduced activity formutations in theDNAbindingdomain and variably reduced activity
for other mutations. Dominant negative effect of the mutations was excluded. We found high
variability and thus no apparent genotype-structure-function-phenotype correlation. Histological
studies of testes revealed vacuolization of Leydig cells due to fat accumulation.
Conclusions: SF-1/NR5A1mutations are frequently found in 46,XY DSD individuals (9%) andman-
ifest with a broad phenotype. Testes histology is characteristic for fat accumulation and degen-
eration over time, similar to findings observed in patients with lipoid congenital adrenal hyper-
plasia (due to StAR mutations). Genotype-structure-function-phenotype correlation remains
elusive. (J Clin Endocrinol Metab 97: E1294–E1306, 2012)
Steroidogenic factor-1 (SF-1; also called Ad4BP) is a nu-clear receptor that regulates adrenal and reproductive
development and function (1, 2). It is considered a master
transcriptional regulator of genes involved in the hypotha-
lamic-pituitary-gonadal and adrenal axes. SF-1 regulates the
transcriptionofmanygenes involved in steroidogenesis, sex-
ual development, and reproduction (2). However, detailed
regulation of SF-1 expression itself and its downstream ef-
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fects remain to be elucidated (2). The human SF-1 protein
consists of 461 amino acids and is encoded by the NR5A1
gene (3). It is expressed in the fetal and adult adrenal cortex
as well as in fetal and adult testes and ovaries (2).
Human NR5A1 mutations were first described in
46,XY individuals with combined adrenal failure and dis-
orders of sexual development (DSD) (4, 5). To date, only
one case with apparently isolated primary adrenal failure
has been reported in a 2-yr-old 46,XXgirl (6). By contrast,
manyNR5A1mutations have been found in a large num-
ber of 46,XY DSD individuals with apparently normal
adrenal function (7–16), as well as in several 46,XX in-
dividualswith normal female sexual development but pre-
mature ovarian failure (17, 18). Some cases were familial
(5, 10–12, 17–20), and some were sporadic (12, 17). Be-
sides the aforementioned phenotypes,NR5A1 mutations
are associated with a very wide range of phenotypes re-
lated to reproductive function anddevelopment (21), such
as hypospadias (13, 22), anorchia (10), isolated micrope-
nis (23), male infertility (24), and primary ovarian insuf-
ficiency (POI) (2, 10, 17, 18, 21).
Since the first description ofNR5A1mutations in 1999
(4), over 50 mutations have been reported. Most subjects
carry mutations in a heterozygote state (4, 6, 7, 9, 10,
12–18, 20, 22–26), some are compound heterozygous (8,
11, 12, 17, 24), and only a few are homozygous (5, 27).
Although many patients with NR5A1 mutations have
been studied extensively, no clear genotype-phenotype
and SF-1 protein structure-function correlation has been
found. The search for modulating factors explaining the
broad range of clinical manifestations of NR5A1 muta-
tions continues.
In this study, 10novelNR5A1mutations are described.
Nine mutations were identified in 46,XY DSD patients
and one in a 46,XX POI patient. Clinical, biochemical,
histological, and genetic data of the patients are presented.
Functional studies and protein structure analyses of the
novelNR5A1mutations were performed to study pheno-
type-genotype correlations.
Patients and Methods
Patients and ethical approval
A total of 102 patients of Spanish, Turkish, and Swiss origin
were analyzed formutations in theNR5A1 gene. The 65 Spanish
Pediatric Endocrinology Research Unit (N.C., M.F.-C., P.A., A.C., L.A.), Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Universitat Auto`noma de Barcelona, Center
for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 08035 Barcelona, Spain; Pediatric Endocrinology (N.C., A.V.P., M.J., P.E.M., C.E.F.), Department of
Pediatrics and Department of Clinical Research, University Children’s Hospital Bern, 3010 Bern, Switzerland; Pathology Department (N.T.), Hospital Universitari Vall d’Hebron, Universitat
Auto`noma de Barcelona, 08035 Barcelona, Spain; Pediatric Endocrinology (F.M.), Hospital Universitari I Polite`cnic La Fe, 46026 Valencia, Spain; Department of Pediatrics (A.B.), Division
of Pediatric Endocrinology, Marmara University, 34722 Istanbul, Turkey; Department of Pediatrics (T.A.), Division of Pediatric Endocrinology, Sisli Etfal Education and Research Hospital,
34377 Istanbul, Turkey; Pediatric Endocrinology (E.G.-G.), Hospital Vírgen del Rocío, 41013 Sevilla, Spain; Pediatric Endocrinology (M.T.M.), Hospital Infantil Universitario del Nin˜o Jesu´s,
Pediatric Department, Autonomous University, 28049 Madrid, Spain; Pediatric Endocrinology (R.G.), and Pathology Departments (M.N.), Hospital La Paz, 28046 Madrid, Spain; and
Research Institute (L.C.), Hospital de Cruces/Universidad del País Vasco-Euskal Herriko Unibertsitatea, CIBERER, Instituto de Salud Carlos III, 48903 Barakaldo, Bizkaia, Spain
TABLE 1. Clinical, biochemical, anatomic, and genetic characteristics of the 10 patients harboring novel mutations
in the NR5A1 gene
Patient no. Origin, YOB Karyotype/assigned sex Genital anatomy Testes histology (age)
1 Spanish, 2008 46,XY/male Scrotal hypospadia. Bilateral cryptorchidism. No Müllerian ducts ND
2 Spanish, 1981 47,XYY/female Female external genitalia. Bilateral inguinal hernia. No Müllerian ducts Abnormal (3.5 yr), Fig. 3A
3 Spanish, 1971 46,XY/female to male at
18 yr
Ambiguous external genitalia at birth. Progressive virilization at puberty
with nonpalpable gonads. No Müllerian ducts
Cryptorchidic, dysgenetic testes (19 yr)
4 Turkish, 1997 46,XY/female Ambiguous external genitalia. Bilateral inguinal hernia. No Müllerian ducts Seminiferous tubules devoid of spermatogonia
5 Spanish, 1998 46,XY/female Female external genitalia. Bilateral inguinal hernia. No Müllerian ducts No histology upon gonadectomy (1 yr)
6 Spanish, 2006 46,XY/female Ambiguous external genitalia. Gonads palpable in labia majora. No
Müllerian ducts
Testis biopsy (4 yr): seminiferous tubules with variable
diameters; some without germ cells. Few Leydig
cells in interstitium
7 Spanish, 2003 46,XY/female Female external genitalia. Gonads in labia majora. No Müllerian ducts Abnormal (2 yr), Fig. 3, B and C
8 Spanish, 2003 46,XY/female to male at
8 months
Ambiguous genitalia (Prader 3). Palpable gonads. No Müllerian ducts Abnormal (2 yr), Fig. 3D
9 Swiss, 1994 46,XX/female Normal female at birth. Pelvic US (16 yr), prepubertal uterus,
nondetectable ovaries
ND
10 Turkish, 2009 46,XY/male Ambiguous genitalia (Prader 3). Palpable gonads. No Müllerian ducts ND
YOB, Year of birth; F, father; M, mother; (N), normal sequence; SRD5A2, 5-reductase type 2 gene; LHCGR, LH receptor gene; CYP17A1,
cytochrome P450 17-hydroxylase/17,20-lyase gene; US, ultrasound; ND, not done; T, testosterone; E2, estradiol; AMH, anti-Müllerian hormone
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patients included 61 subjects with 46,XY DSD, one with
47,XYYDSD, and three 46,XY patients with anorchia.AR (an-
drogen receptor) and SRD5A2 (5-reductase type 2) genes had
been previously analyzed in these patients andwere normal in all
except one carrying the P378R AR mutation (28). In some, the
CYP17A1, HSD17B3, and LHCGR genes were analyzed for
mutations, but none were found (Table 1). Similarly, a group of
35 Turkish patients with 46,XYDSD and two Swiss POI 46,XX
patients were evaluated. AR and SRD5A2 genes were analyzed
in all 35 Turkish patients, but no mutations were detected. The
Swiss patients were only analyzed for NR5A1 mutations.
All studied subjects and/or their legal guardians gave written
informed consent for the biochemical and molecular studies,
which were approved by the respective ethical committees of the
three study centers.
Genetic analyses
Genetic analyses of the NR5A1 gene were performed as ex-
plained in Supplemental Data and Supplemental Table 1 (pub-
lished on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org).
In vitro functional studies
In vitro functional studies were performed in human steroid-
ogenic NCI-H295R and nonsteroidogenic HEK293 cells (see
Supplemental Data and Supplemental Table 1).
In silico protein structure analysis
For bioinformatic studies, the mouse SF-1 DNA binding do-
main (DBD) NMR structure (PDB no. 2FF0; N terminus, AA
10-111, 100% similar to human SF-1) and human SF-1 ligand
binding domain (LBD) x-ray crystal structure (PDB no. 1ZDT;
C terminus, AA 221-461) were used (see Supplemental Data).
Results
Identification of 10 novel NR5A1 gene mutations
in patients presenting with 46,XY DSD or 46,XX
POI
We found 10 novel, disease-causing mutations in the
NR5A1 gene in a combined group of 102 patients pre-
senting with 46,XYDSD (eight of 99; 8%), 47,XYYDSD
(one of one), or 46,XX POI (one of two). All details of the
patients’ characteristics are summarized in Table 1, and
individual case reports are available as Supplemental
Data.
Six of nine 46,XY subjects harboring NR5A1 muta-
tionspresentedwithambiguousgenitalia atbirthandwere
assigned eithermale (two of six) or female (four of six) sex
of rearing. Patients 3 and 8, whowere initially assigned to
female sex were assigned to male sex at age 18 yr and 8
months. Three 46,XY subjects presented with normal ex-
ternal female genitalia but were noted to have either in-
guinal hernia at the age of 2–3 yr or palpable gonads in
labia majora at age 2 wk. Gonadal function was tested
in nine subjects and found to be abnormal in seven of the
46,X(Y)Y. Six subjectswere gonadectomized at ages 2–19
yr, and a testis biopsywas performed in one aged 4 yr. The
single 46,XX female patient presented with absent puber-
tal signs at age 15 yr due to POI/hypergonadotropic hy-
pogonadism.None of the patients had a history of adrenal
insufficiency, but adrenal function was only evaluated in
six patients, suggesting normal function in five (using vari-
TABLE 1. Continued
Gonadal function (age) Adrenal function (age) NR5A1 gene mutation Family Previous genetic studies
Normal baseline (1 d and 1 yr) Normal baseline (1 d and 1 yr) c.58GC; Val20Leu F  carrier, M WT AR (N), SRD5A2 (N)
Abnormal (T slightly decreased and normal
precursor response to hCG) (3 yr)
Normal baseline (30 yr) c.70CT; His24Tyr Brother and sister WT AR (N), SRD5A2 (N)
Abnormal (normal T and precursors, high LH
and FSH) (18 yr)
Normal baseline (18 yr) c.70delC; His24ThrfsX51 Sister  carrier (infertility). (History of
early menopause in M and of
ambiguous genitalia in maternal
great aunt)
Patient AR (N), SRD5A2 (N).
Patient and sister, LHCGR
(c.51_52insTGCAGC
polymorphism)
Abnormal (no T response to hCG) (1 yr) ND c.90TG; Cys30Trp AR (N), SRD5A2 (N)
ND Normal (22 months) c.268GC; Gly90Arg M  carrier. (History of ambiguous
genitalia in maternal great uncle
and of early menopause in M
and grandmother)
AR (N), SRD5A2 (N)
Abnormal (low T and normal precursor response
to hCG) (7 months)
ND c.389delC; Pro130ArgfsX165 F WT, M WT AR (N), SRD5A2 (N)
Abnormal (no T response to hCG) (14 d) Abnormal? (slightly increased
ACTH and decreased
precursor response to
Synacthen) (6 yr)
c.614_615insC; Gln206ThrfsX20 AR (N), CYP17A1 (N)
Abnormal (no T response to hCG) (1 month) ND c.690_691dupCTGCAGCTG;
Leu231_Leu233dup
F WT, M WT AR (N), SRD5A2 (N)
Abnormal (increased LH and FSH and
undetectable E2 and AMH) (15 yr)
Normal (15 yr) c.704CT; Pro235Leu
Normal baseline (2 months) ND c.905GA; Trp302Stop AR (N), SRD5A2 (N)
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able assessments, e.g. basal or stimulated tests) andminor
abnormalities such as slightly increased ACTH and de-
creased cortisol precursor secretion in subject 7. Family
history and/or genetic testing of relatives revealed other
affected family members in at least two subjects (one
healthy 46,XY carrier excluded), but it was only available
from six families.
The 10 novel mutations in theNR5A1 gene were scat-
tered throughout exons 2 to 5 (Figs. 1 and 2). Nine mu-
tationswere single nucleotide changes that led to six point
mutations (five missense and one nonsense) and three
frameshift mutations (two deletions and one insertion). A
duplication of nine nucleotides (in-frame) was also de-
tected, leading to an insertion of three amino acids and a
prolongation of the protein sequence.
Three mutations were found in other family members
(cases1,3, and5),whereas themutationsPro130ArgfsX165
and Leu231_Leu233dup appeared to be de novomutations
FIG. 1. Diagram of the NR5A1 gene and chromatograms of the 10 novel mutations. The mutations identified in patients and their exact location
in the NR5A1 gene sequence are shown. In the NR5A1 gene diagram, numbers refer to exons 1 to 7 and noncoding sequences are shown in gray.
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in patients 6 and 8 because both of their parents were non-
carriers (Table 1).
In addition, the polymorphism Gly146Ala (c.437GC)
(rs1110061) was identified in seven of 102 (6.8%) 46,XY
DSD subjects (Table 2). Sixwere heterozygous,whereas one
was homozygous (subject 17). Subject 17 also carried two
other sequence variations: Pro125Pro (rs1110062) in the
NR5A1 gene, and Pro378Arg in the AR gene (28).
Histopathology findings of testes in patients with
heterozygote NR5A1 mutations
Testis tissue for histopathological studieswas available
from five patients aged 2 to 4 yr (patients 2, 4, 6, 7, and 8;
Fig. 3 and Table 1). Gonadal function in those subjects
appeared tobe abnormal (Table 1).Tis-
sue sections were compared with nor-
mal control tissue and testis tissue orig-
inating from a patient with lipoid
congenital adrenal hyperplasia owing
to StAR mutations (Fig. 3). Morphol-
ogy of testis tissues obtained before pu-
berty from patients harboring hetero-
zygote NR5A1 mutations revealed
diminished tubular diameter and absent
or decreased spermatogonia. Intersti-
tium was remarkable for cell nests with
vacuolized, xanthomatous, or adipo-
blast-like Leydig cells (Fig. 3, A, B, and
D). Osmium staining revealed osmium-
positive lipid deposits (Fig. 3C), not
present in control testis (Fig. 3F), and
which resembled the Leydig cells typi-
cally observed in prepubertal testes of
patients with lipoid congenital adrenal
hyperplasia (Fig. 3E).
In vitro functional studies of the
novel NR5A1 mutations
Functional activity was tested by
studying transactivation of wild-type
(WT) and mutant NR5A1 on promot-
ers of genes for steroidogenic enzymes
regulated by SF-1 in steroidogenic and
nonsteroidogenic cell models (Fig. 4).
Transfection of human adrenal NCI-
H295R cells with WT and NR5A1 mu-
tants together with a CYP17A1 pro-
moter reporter construct revealed that all
10NR5A1mutations had impaired abil-
ity to stimulate the CYP17A1 promoter
(Fig. 4A). Among the 10 mutants,
Pro235Leu (identified in a 46,XX POI
patient; Table 1)wasmost active, having
80% of WT activity. Overall, mutations located in the
DBD (cases 1–5) appeared to be functionally less active
than mutations in the LBD (cases 8–10). Studies of SF-1
transactivating the CYP11A1 and HSD3B2 promoters
were not possible in NCI-H295R cells because back-
ground activity of endogenous SF-1was too high and pro-
moter stimulation usingWToverexpression too low (data
not shown). Therefore, we performed further studies in
nonsteroidogenic HEK293 cells, which do not express
SF-1. Similar toNCI-H295R cells, all 10NR5A1mutants
had impaired activity on the CYP17A1 promoter (Fig.
4B). Again, the Pro235Leu mutant displayed highest ac-
tivity (80% of WT), and mutations in the LBD seemed
slightly more active than mutations in the DBD.
FIG. 2. Diagrams of the WT and mutated SF-1 peptide sequences. A, Diagram of the WT SF-
1 protein; B, predicted peptide sequences of the 10 SF-1 mutations. Four mutations are
located in the core domain and one is located in the Ftz-F1 box domain of the DBD. The
hinge region contains two mutations, and the LBD contains the remaining three. All
mutations were found to be heterozygous. In the diagrams, point mutations are shown as
vertical bars (indicated by arrows), and sequence changes are given as horizontal lines, shown
in red. In panel A, numbers above the diagram indicate the amino acid at the start of the
protein domain or those contained in the domain (for AF-2) (19, 34, 35). N-t, N terminal; C-t,
C terminal; Zn I, first zinc finger; Zn II, second zinc finger; AF-2, activation function domain 2.
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However, studies of SF-1 activating the CYP11A1 and
HSD3B2 promoters in HEK293 cells confirmed these re-
sults only partially (Fig. 4, C and D). NR5A1 mutations
located in the DBD (1–4) showed a profound loss of
CYP11A1 and HSD3B2 promoter stimulation similar to
the CYP17A1 promoter. But in contrast to the CYP17A1
promoter, all NR5A1 mutants located in the LBD (8–10)
had either unchangedactivity in stimulating theCYP11A1
or HSD3B2 promoters or even higher activity (Trp302X
on HSD3B2). Promoter studies of the NR5A1 mutants
located in the Ftz-F1 box (case 5) and hinge region (cases
6 and 7) showed mixed results (Fig. 4, C and D).
Because all our patients harbor heterozygote NR5A1
mutations, the dominant negative effect of mutants over
theWTNR5A1was assessed in our cell model. Similar to
other investigators testing various NR5A1 mutations
(6–8, 11, 12, 14, 20, 29), our reporter assays did not
reveal a dominant negative effect for anymutant (Fig. 4E).
Thus, the mechanism of heterozygote NR5A1 mutations
causing the phenotype of DSD in our patients remains a
conundrum. To assess the expression ofNR5A1 variants
in our cell model, we performed Western blots (Fig. 4F).
These studies showed that transiently transfected cells
expressed all WT and mutant SF-1 proteins. Only
His24ThrfxX51 seemed to be too small to be detected on
our blot. On our Western blots, no significant differences
were seen in protein expression ofmutant SF-1when com-
paredwithWT.Yet, somemutants rather showedahigher
level of expression (Gly90Arg, Pro235Leu).
Studies of the Gly146Ala variant on promoter activity
of CYP17A1 in HEK293 cells revealed no effect overall
and also no dominant negative effect in particular (Sup-
plemental Fig. 1).
In silico protein structure analysis
Human SF-1 protein has two distinctive domains. The
DBDcontains a corewith twoCys4-zinc-fingermotifs and
a highly conserved Ftz-F1 box that includes a highly con-
served RGGR motif potentially involved in interaction
with DNA.Mutants Val20Leu, His24Tyr, and Cys30Trp
arepresent in theDBDcore, andGly90Arg is located in the
RGGRmotif of the Ftz-F1 box (Fig. 5A). The Pro235 and
Leu-Gln-Leu repeats are located at the N terminus of the
LBD (Fig. 5B).
In the three-dimensional structure, the four DBD mu-
tations are located in a critical hotspot that comprises the
C terminus of the DNA-recognition helix, the -hairpin
loop, and the RGGR motif in the loop before the critical
C-terminus helix of DBD required for stability of the SF-
1/DNA complex (Fig. 5A). All these mutations are in the
region that directly interacts with DNA and may alter the
pattern/recognition of specific DNA sequences. A change
from Val20 to Leu causes alterations in the side chain
packing environment of the N-terminal loop due to inter-
action of altered Leu20 with Asp10 and Glu11 (Fig. 5C).
Thismay slightly alter theDBDstructure and influence the
interaction with DNA molecule. However, a major con-
formational change that could have a major influence on
DNA binding was not expected. The His24 residue is cru-
cial for DNA binding, and its substitution with Tyr shifts
theTyr side chain away from theDNAbinding site, break-
ing the hydrogen bond (Fig. 5D). The Cys30 residue is
essential for zinc binding and stability of the core DBD. In
silico mutagenesis and molecular dynamics simulations
were used to change the Cys30 to Trp, and resulting struc-
ture shows the disruption of a Cys-zinc contact resulting
in an unstable core structure (Fig. 5E). The mutation
Gly90Arg is located in the RGGR motif formed by R89-
R92 in human SF-1 (in the loop before the C-terminus
helix in Ftz-F1 box). Themutation of Gly90 to Arg results
in amajor change at the DNA binding site due to the large
positively charged Arg side chain (Fig. 5F). The change
from Gly to Arg will alter the binding pattern and may
have variable effects depending on sequence of DNA in-
teraction partner. Additional interactions with DNA will
be createddue toArg side chainat thebinding site thatmay
change binding selectivity and result in activation of dif-
TABLE 2. Clinical, biochemical, and anatomic characteristics of seven 46,XY DSD patients harboring the Gly146Ala
NR5A1 sequence variation
Patient no. Origin, YOB Karyotype/assigned sex Genital anatomy Testes histology (age)
11 Spanish, 1996 46,XY/female to male (1 yr) Scrotal hypospadias. Bilateral cryptorchidism. No Müllerian ducts ND
12 Spanish, 2001 46,XY/male Scrotal hypospadias. Bilateral cryptorchidism ND
13 Turkish, 2001 46,XY/male Scrotal hypospadias. Bilateral palpable gonads ND
14 Turkish, 2002 46,XY/male Scrotal hypospadias. Bilateral palpable gonads ND
15 Turkish, 2005 46,XY/male Scrotal hypospadias. Bilateral palpable gonads ND
16 North African, 2008 46,XY/male Ambiguous external genitalia. Gonads palpable in labia majora.
Müllerian duct remnants present
ND
17 Sub-Saharan, 1998 46,XY/male Scrotal hypospadias. Intraabdominal testes. Müllerian duct
remnants present
Normal prepubertal interstitium. Sertoli cell
hyperplasia and lack of spermatogonia (4 yr)
YOB, Year of birth; (N), normal sequence; SRD5A2, 5-reductase type 2 gene; AMH, anti-Müllerian hormone gene; AMHRII, AMH receptor type 2;
ND, not done; T, testosterone.
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ferent promoters and may have variable effects on indi-
vidual promoters.
The Pro235 separates the twoN-terminus helices of the
LBD of SF-1 (Fig. 5G). The mutation Pro235Leu may
abolish the break in between two helices and creates a
larger single helix. Such a change will not result in the
alteration of the core structure but may cause subtle
changes in the neighboring residues near the ligand bind-
ing site. A likely effect would be modification of ligand
binding and recognition and may have variable effects
depending on specific ligands. The dual repeat units of
Leu-Gln-Leu located at the N terminus of LBD form the
N-terminal helix. The insertion of another Leu-Gln-Leu
repeat unit changes the composition of this helix and re-
sults in a longer loop structure located in between the two
N-terminal helices (Fig. 5H). The addition of extra Leu
side chain from Leu-Gln-Leu insertion creates changes in
the environment of neighboring residues to accommodate
the extra Leu side chain pointing toward the core of the
LBD. The specific effect of such a change is unpredictable,
and a variable effect depending on specific ligand is ex-
pected. Both the Pro235LeuandLeu-Gln-Leu insertiondo
not appear to alter the ligand-bindingproperties, and their
effects may therefore be related to relatively minor
changes caused by altered flexibility of the two N-termi-
nus helixes.
Discussion
We found 10 new mutations in the NR5A1 gene in 102
patients studied for either 46,XY DSD or 46,XX POI
(9.8%). These mutations were all heterozygous and were
predominantly single-nucleotide changes.
Individuals with heterozygousNR5A1mutations pres-
ent with a broad range of phenotypes covering completely
normal phenotype to severe forms of 46,XY DSD or POI
in 46,XX subjects (2, 16, 17, 21, 24). Even identical mu-
tations within families may lead to differing phenotypes
(10, 17–19). Similarly, our patients presented with a wide
clinical spectrum. External genitalia in 46,XY individuals
varied from completely female to ambiguous with cryp-
torchid testes; none presented with Mu¨llerian duct rem-
nants. Gonadal steroid production studied at prepubertal
age ranged from apparent lack of testosterone secretion to
only slightly diminished testosterone response upon hu-
man chorionic gonadotropin (hCG) stimulationwith nor-
mal steroid precursors. Only one patient developed spon-
taneous puberty and reached a normal male adult serum
testosterone level but had grossly elevated gonadotropin
levels. Adrenal function appeared to be normal in most
patients but was not assessed in all. However, adrenal
function should be followed in patients withNR5A1mu-
tations because adrenal insufficiency has been described
withNR5A1mutations and may only develop over time.
Family history of two patients (cases 3 and 5) revealed
ambiguous genitalia and premature menopause in several
relatives, ofwhomsomewere also found tohave heterozy-
gousNR5A1mutations. By contrast, the father of a mod-
erately affected 46,XY DSD patient (case 1) was pheno-
typically normal but was a carrier of Val20Leu. Similarly,
normal carriers with heterozygous NR5A1 mutations
have been reported (10, 16, 22). Arg281Pro located in the
LBD was found in a 46,XY DSD patient who had hypos-
padias and micropenis and a phenotypically normal car-
rier father (16). Val355Met was detected in a boy with
micropenis and testicular regression syndrome and a nor-
mal carrier brother (10). Thus, the wide range of pheno-
types of individuals with mutations in the NR5A1 gene
includes normal sexual development, or at least normal
enough to guarantee fertility.
Overall, we analyzed testis tissue of five heterozygous
NR5A1 patients (Table 1 and Fig. 3) and found similar
alterations as seen in patients with mutations in the ste-
roidogenic acute regulatory protein (StAR). StAR medi-
ates cholesterol transfer into the mitochondrion toward
the P450ssc enzyme cleavage system (30, 31). Therefore,
TABLE 2. Continued
Gonadal function (age) Adrenal function (age) Family NR5A1 gene Other genes studied
Abnormal (subnormal T response to hCG) (2 yr). (T
decreased and LH  FSH increased) (13 yr)
Normal (1 month) Hetero c.437GC; Gly146Ala AR (N)
Normal (T response to hCG) (1.5 yr) Normal (3 yr) Hetero c.437GC; Gly146Ala AR (N)
Abnormal (subnormal T response to hCG) (1 yr) Normal (1 yr) Hetero c.437GC; Gly146Ala AR (N), SRD5A2 (N)
Abnormal (decreased T response to hCG) (1 yr) Normal (1 yr) Consanguinity Hetero c.437GC; Gly146Ala AR (N), SRD5A2 (N)
Normal (T response to hCG) (2 yr) Normal (2 yr) Hetero c.437GC; Gly146Ala AR (N), SRD5A2 (N)
Normal baseline (10 d). Abnormal (T slightly decreased
and normal precursor response to hCG) (3 months)
Normal (10 d) Hetero c.437GC; Gly146Ala AR (N)
Normal baseline (5 d) Normal baseline (5 d, 4 months) Parents first cousins Homo c.437GC; Gly146Ala. Homo
c.375GA; Pro125Pro
AR (c.1139CG; Pro378Arg) (Ref. 28),
AMH (N), AMHRII (N)
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severe StAR deficiency causes intracellular accumulation
of lipids and disrupts steroidogenesis. Leydig cells of pa-
tients with SF-1 mutations may also be defective in the
conversion of cholesterol to pregnenolone (mediated by
CYP11A1/P450ssc). In addition, SF-1 deficiency affects
further enzymes of steroidogenesis. Thus, similar mecha-
nisms may cause vacuolization of Leydig cells due to ac-
cumulation of lipid droplets not processed by steroido-
genesis. In our tissue samples, osmium staining confirmed
this for the first time, although other reports have pre-
sented histological data for testis of subjects withNR5A1
mutations without describing lipid accumulation (4,
7–11, 14, 17–20, 22, 24, 26).
Overall, data suggest a progressive degeneration of the
testicular tissue in individuals with mutations inNR5A1.
Relatively preserved testicular architecture
progresses to dysgenesis in babies and to re-
placement with connective tissue causing loss
of seminiferous tubules and leading to absence
of gonadal tissue in adults. Regarding the cel-
lular profile, children of young ages up to pu-
berty have rare germcells (9, 11, 14, 17, 20, 22,
26) and nests of (vacuolized) Leydig cells (11,
14, 17–20, 26). 46,XY DSD patients carrying
heterozygous SF-1 mutations (with undervir-
ilization and diminished fertility index) dem-
onstrate that testosterone secretion is variably
affected in fetal life and may progress, proba-
bly due to interstitial cell degeneration, similar
to what occurs in patients with StAR muta-
tions. Similarly, but at puberty or even later,
46,XX carrier females present with ovarian in-
sufficiency (10, 17, 18). Because this process
appears to affect steroidogenesis of only the go-
nads and not the adrenals, the evolution appears
reverse to nonclassic congenital lipoid adrenal
hyperplasia due to mild StARmutations, where
gonadal function may be preserved into adult-
hoodwhereasadrenal insufficiencyusuallyman-
ifests at a young age (32, 33).
The 10 novel NR5A1 mutations desc-
ribed in this paper are located in exons 2 to
5 (Figs. 1 and 2). Generally, mutations in the
DBD region that is crucial for transcription
factor binding to promoters (2) are more se-
vere. The first four mutations (Val20Leu,
His24Tyr, His24ThrfsX51, and Cys30Trp)
are located in the first zinc-finger domain of
the DBD but not in the P box. Thus, they are
involved in the binding of the major groove
of DNA but not in the specific recognition of
the DNA target sequence (hormone response
element) (2). His24ThrfsX51 will result in a
truncated protein with total loss of function. Gly90Arg is
located in the Ftz-F1 box,which is considered a stabilizing
region for the binding of SF-1 to DNA (2, 34, 35).
Pro130ArgfsX165 and Gln206ThrfsX20 in the hinge re-
gion result in a truncated protein with no LBD, whichwill
lead to an inactive SF-1. The remaining mutations
(Leu231_233dup, Pro235Leu, and Trp302Stop) are lo-
cated in the LBD. This regionmodulates SF-1 activity ow-
ing to its C-terminal AF-2 domain, which binds phospho-
lipid ligands (2, 20, 36, 37) and other cofactors (2). Thus,
mutations in the DBD are expected to lead to markedly
affected transactivation assays, whereas LBD mutations
may have varying effects depending on their location and
alterations in the ligand specificity/recognition.
FIG. 3. Histology findings of testes of patients 2, 7, and 8 with heterozygous
NR5A1 mutations. A, Hematoxylin eosin stain (HE) Image originates from patient 2
(47,XYY DSD) at the age of 3.5 yr and shows interstitial tissue (between two
seminiferous tubules) with some Leydig cells (one is circled) with cytoplasmic
vacuoles (arrow). B and C, Images belong to patient 7 (46,XY DSD) at the age of 2
yr. B, Trichrome stain image shows interstitium surrounded by different seminiferous
tubules. In these tubules, with a thin tunica propria, there are predominantly Sertoli
cells but no spermatogonia; only a few nests of xanthomized Leydig cells (arrow) can
be seen in the interstitium. C, Osmium stain image reveals that the cytoplasmic
vacuoles of Leydig cells contain lipids (dark brown staining indicates osmium
deposits). D, Image originates from patient 8 (46,XY DSD) at the age of 2 yr and
shows seminiferous tubules full of pre-Sertoli cells but without germ cells. As in
patient 7, the interstitium contains some nests of Leydig cells (circled) with a
xanthomatous appearance. None of these structures can be seen in normal testes. E,
Image depicts testis histology (HE) of a patient with StAR mutations at age 3 yr
showing similar histological findings as seen in our NR5A1 patients. F, Image
corresponds to an osmium histochemical staining of normal testis tissue originating
from a 2-yr-old subject without any positivity in Leydig cell cytoplasm (circle).
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FIG. 4. Functional and expression studies of the 10 novel NR5A1 mutations. A–D, The ability of WT and mutant NR5A1 to activate steroidogenic
enzyme promoter luciferase reporter constructs was tested in adrenal NCI-H295R cells (A) and nonsteroidogenic HEK293 cells (B–D). A–C, Cells
were transiently transfected with NR5A1 expression vectors and CYP17A1 (A and B), CYP11A1 (C), and HSD3B2 (D) promoter reporter constructs.
E, Similarly, the impact of the mutants on the activity of the WT SF-1 was checked by transfecting the 10 different mutants with or without WT
NR5A1 expression vector together with the CYP17A1 promoter reporter construct in HEK293 cells. No dominant negative effect was observed.
A–E, Luciferase activity was measured with the Promega Dual Luciferase assay system. Results are expressed as percentage of WT activity, which
was set at 100% RLU, and represent the mean and SEM of two to four independent experiments performed in duplicate. F, Western blot showing
expression of WT and mutant SF-1 proteins. Hemagglutinin-tagged SF-1 was recognized by HA antibody in the Western blot (band at 53 kD). B-
actin was used as a control. Note that His24ThrfsX51 was not detected for its small weight/size. *, P  0.05; **, P  0.01; ***, P  0.001; #,
p.Pro235Leu is statistically different from all other mutants (P  0.001); °, Numbers indicate average fold increase of WT over Ve. RLU, relative
light units; Ve, empty vector control; HA, hemagglutinin.
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Invitropromoter transactivationassayshavebeenused
previously to assess the functional impact of sequence
variations (4, 6). Therefore, we tested the 10 novel SF-1
variants for their ability to transactivate different promot-
ers of steroidogenic enzymes in steroidogenic adrenal
NCI-H295R and nonsteroidogenic human embryonic
kidneyHEK293cells.We found that SF-1mutations in the
DBD consistently showed impaired transactivation activ-
FIG. 5. Structural analysis of SF-1 mutations. In the figures showing the mutated amino acids, the mutant and WT structures have been
superimposed; mutant residues are shown in red, whereas WT residues are shown in green. The structures are drawn as ribbons; model and
location of mutated amino acids described in this study are shown as stick models. A, Location of mutations in the DBD of the SF-1 protein. B,
Structure of SF-1 LBD showing the location of mutations. C, Effect of Val20Leu on SF-1 DBD structure. A change from Val (shown as green sticks)
to Leu causes alterations in the side chain packing environment of the N-terminal loop due to interaction of altered Leu residue (shown as red
sticks) with the Asp10 and Glu11. This may modify the core DBD structure and alter the interaction with DNA molecule. D, Effect of His24Tyr
mutation of SF-1 DNA interaction. The His24 residue is crucial for DNA binding, and its substitution with Tyr alters the interaction due to a shift of
Tyr side chain away from the DNA binding site, breaking the hydrogen bond interactions. E, The Cys30Trp mutation on zinc binding in the human
SF-1 structure. The structure of DBD of SF-1 in complex with DNA is shown as in panel A, the zinc ion is shown as an orange sphere, and Cys
residues involved in zinc binding are shown as stick models, with Trp30 change shown in red. In silico mutagenesis and molecular dynamics
simulations were used to change the Cys30 to Trp, and the resulting structure was superimposed on normal structure for analyzing the changes.
The change of Cys30 to Trp results in disruption of a Cys-zinc contact, resulting in an unstable structure. F, Effect of Gly90Arg mutation. The
Gly90 residue is located near the DNA binding site, and its mutation to Arg results in a major change at the binding site due to the large positively
charged Arg side chain. The change from Gly to Arg will alter the binding pattern and may have variable effects, depending on the sequence of
DNA interaction partner. Additional interactions with DNA will be created due to the addition of Arg side chain at the binding site. G, Effect of
Pro235Leu mutation in the LBD of SF-1. The Pro235 separates the two N-terminus helices of the LBD of SF-1. The mutation from Pro to Leu may
abolish the break between two helices and create a larger single helix. Such a change will not result in the alteration of the core structure but
causes subtle changes in the neighboring residues near the ligand binding site. A likely effect would be modification of ligand binding and
recognition and may have variable effects depending on specific ligands. H, Effect of Leu-Gln-Leu insertion on LBD domain of SF-1. The dual
repeat units of Leu-Gln-Leu located at the N terminus of LBD form the N-terminal helix, and insertion of another Leu-Gln-Leu repeat unit changes
the composition of this helix and results in a longer loop structure located between the two N-terminal helices. The addition of an extra Leu side
chain from Leu-Gln-Leu insertion creates changes in the environment of neighboring residues to accommodate the extra Leu side chain pointing
toward the core of the LBD. Specific effects of such a change are hard to predict, and a variable effect depending on specific ligand is expected.
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ity when studied on different promoters and in different
cell systems. By contrast, promoter studies of mutations
located outside the DBD showed a more variable picture
with different promoters or cell systems. For NR5A1,
Pro235Leu minor changes in activity were found leaving
the question open whether this mutation may be disease
causing. The observation that functional tests correlate
poorly with phenotype was also made by several other
investigators (6, 7, 10, 20, 38) indicating that results from
these studies may be of limited value and that testing of
several promoters in different cell systems may be neces-
sary to assess the functional impact of NR5A1 sequence
variations. Because most patients harbor heterozygote
NR5A1mutations, dominant negative effect may be con-
sidered and was therefore tested. However, we and others
(6–8, 11, 12, 14, 20, 29) did not find experimental con-
firmation for such a mechanism of mutant SF-1 over WT
protein in cell models. In vitro protein structure studies
have not been able to give a clear picture on the structure-
function correlation of sequence variations in LBD.
In addition to the diversity ofNR5A1mutations in the
in vitro studies, phenotype variability of NR5A1 muta-
tions in patients make a genotype-phenotype correlation
(so far) impossible. Because SF-1 is a transcription factor,
(co-)modulatorsmay play a pivotal role, and their number
may have been underestimated in the past. In a recent
publication, ChIP-on-chip analysis revealed a large num-
ber of new SF-1 targets that are currently under further
investigation (39). Thus, the conundrum of variability in
SF-1mutationsmay be explained by additional variations
in cofactors.
In our group of 46,XY DSD patients, we found the
NR5A1 polymorphism Gly146Ala (rs1110061) in 6.8%
(Table 2). It has been detected in other 46,XY DSD pa-
tients (8, 11, 12) and 46,XX subjects with sporadic POI
(17). Its allele frequency varies depending on the control
population studied (http://www.ncbi.nlm.nih.gov/) and
occurs frequently in Japanese patients with adrenal dis-
orders (40). It has been associated with micropenis (23,
41) and cryptorchidism (42). Gly146Ala leaves SF-1
transactivation activity unaltered (Supplemental Fig. 1)
and does not affect cofactor interaction and cellular lo-
calization (11, 40). Therefore, it has been considered a
polymorphismonly.However, after finding this polymor-
phism in so many 46,XYDSD subjects, and knowing that
in vitro functional tests are poor predictors, its causal role
remains elusive.
In conclusion, the detection of 10 novel NR5A1 mu-
tations in nine of 100 46,XY DSD patients and in one of
two 46,XX patients with ovarian insufficiency highlights
the crucial role of SF-1 in sexual development and func-
tion. Clinical and biochemical phenotypes of these 46,XY
DSD patients are variable and genotype-phenotype cor-
relation remains elusive. Although functional studies help
in defining the impact ofNR5A1 sequence variations, re-
sults differ depending on the in vitro systems employed.
Overall the SF-1 system is very complex and appears to
involve as yet unknown modulators, whereas dominant
negative effects may be excluded.
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